Introduction
Rap proteins (comprising two Rap1 and three Rap2 isoforms) are GTPases among the most closely related to Ras (Pizon et al., 1988; Kitayama et al., 1989 ), yet Ras and Rap carry out distinct biological functions. Whereas Ras mainly acts to transduce proliferation cues (Bar-Sagi and Hall, 2000) , Rap1 has been thought as a negative regulator of growth through its ability to interfere with the activation of ERK MAP kinases; converging evidence now points out to a role for Rap in the regulation of adhesion (Bos et al., 2001 ). Rap1 activity is required for integrin-mediated adhesion and may act through effectors such as RapL, involved in LFA-1-mediated adhesion to ICAM-1 in lymphocytes (Katagiri et al., 2004) , and RIAM, expressed in many cell types (Lafuente et al., 2004) , to regulate adhesion mediated by b1 and b2 integrins. Rap1 is also necessary for E-cadherin-mediated adhesion between polarized epithelial cells in Drosophila as well as mammalian organisms, and may fulfil this role by acting at the level of cell-cell junctions through its effector AF-6/Canoe (Boettner et al., 2000; Knox and Brown, 2002; Hogan et al., 2004; Price et al., 2004) .
Rap1 is activated in response to many extracellular stimuli, via a large family of guanine nucleotide exchange factors (GEFs) (Bos et al., 2001) . Similarly to the GEFs acting on Ras and Ral, these proteins carry a CDC25 catalytic domain, in tandem with a stabilizing REM (Ras exchange motif) domain (Boriack-Sjodin et al., 1998) . Additional functional domains ensure that these GEFs are responsive to various incoming signals. For instance, C3G was originally identified as a protein associated with the SH3 domain of the Crk adaptor (Ichiba et al., 1999) , and shown to link Rap1 to many growth factor receptors. Epac/cAMP-GEFs contain one (Epac1/cAMP-GEFI) or two (Epac2/cAMP-GEFII) cAMP binding sites and activate Rap1 in response to cAMP; a third member of this family, Repac/GFR, is devoid of cAMP binding sites, and its regulation is poorly understood (see Bos, 2003 for a review). CalDAG-GEF1/RasGRP2 contains domains that bind Ca 2 þ ions and diacylglycerol and are thought to activate Rap1 in response to those signals (Kawasaki et al., 1998; Clyde-Smith et al., 2000) . Finally, two related GEFs contain a PDZ domain as well as an RA domain that binds activated Ras family proteins (PDZ-GEFI/RA-GEF-1 (de Rooij et al., 1999; Liao et al., 1999) and PDZ-GEFII/RA-GEF-2 (de Rooij et al., 1999; Gao et al., 2001)); they have respectively been shown to bind Rap1 in the perinuclear region and M-Ras in the plasma membrane, which could be responsible for the observed activation of Rap1 in both subcellular compartments Liao et al., 2001; Mochizuki et al., 2001; Ohba et al., 2003; Bivona et al., 2004) . Dominant-negative mutants have been instrumental in demonstrating the involvement of many proteins in signalling pathways. H-Ras[S17N] (Feig and Cooper, 1988; Farnsworth and Feig, 1991) constitutes the paradigm of dominant-negative mutants for Ras-related GTPases, and its mechanism of action has been studied in great detail (Lai et al., 1993; Schweighoffer et al., 1993; Jung et al., 1994) . Upon its ectopic overexpression in cells, H-Ras[S17N] acts by titrating GEFs, hence interfering with the activation of endogenous Ras proteins by their cognate incoming signals. GEFs function by inducing the dissociation of GDP bound to GTPases in their resting state. This results in the formation of a bimolecular high-affinity complex between the nucleotide-free GTPase and its GEF; binding of GTP induces the GTPase to shift to its activated conformation, which displays a considerably reduced affinity for the GEF that then dissociates from the GTPase (Feig, 1999) . Ras dominant-negative mutants described to date have a severely impaired affinity for GTP, and to a lesser extent for GDP; as a result, GTP can no longer induce dissociation of the GEF, which remains bound in the high-affinity complex to nucleotide-free Ras (Feig and Cooper, 1988; Farnsworth and Feig, 1991) . Similar mutants, based on the mutation of the residue equivalent to serine 17 in Ras to asparagine, have been generated for many Ras-related proteins such as Ral, Rho, Rac and Cdc42 and effectively act as potent dominant-negative mutants. However, the equivalent Rap1[S17N] mutant is incapable of inhibiting Rap1 activation by C3G in vitro (van den Berghe et al., 1997) as well as in cells (Hogan et al., 2004) ; the fact that it does not exhibit potent dominantnegative properties has severely hampered investigations into the biological roles of Rap1. In order to overcome this limitation, we undertook to generate and select novel dominant-negative mutants of Rap1. Several of them displayed dominant-negative properties in cultured mammalian cells, with differential effects depending on the pathways used to activate Rap1. Moreover, we show that one of these mutants acts as a dominant negative in vivo, by interfering with Drosophila development.
Results

Strategy to screen for novel Rap1 dominant-negative mutants
Because dominant-negative mutants act by trapping GEFs in a high-affinity complex, and are no longer able to activate downstream effectors (Feig, 1999) , we undertook to select such novel Rap1A mutants on the basis of their increased interaction with the Rap GEF Epac2 and their loss of interaction with effectors using yeast two-hybrid screens. Residues 14-19 of Rap1 belong in part to the P-loop, a structure conserved in all nucleoside triphosphate binding proteins that is involved in binding of the b and g phosphates of GTP (Nassar et al., 1995; Cherfils et al., 1997) . Mutations in this region are likely to result in a loss of affinity for GTP, a prerequisite for GTPase mutants to exhibit dominant-negative properties (Feig, 1999) . Effectively, most dominant-negative mutants of Ras family GTPases indeed carry amino-acid substitutions in this domain (Sigal et al., 1986; Feig and Cooper, 1988; Powers et al., 1989; Farnsworth and Feig, 1991; Chen et al., 1994) . We sought to screen a collection of mutants containing all of the possible single amino-acid substitutions at positions 14-19. To do so, we generated six independent libraries, each corresponding to a single position, by the insertion of a mutagenic oligonucleotide totally degenerated for the targeted codon (see Materials and methods and Figure 1 ). The libraries were generated in a construct encoding the human Rap1A protein fused to the N-terminus of the DNA binding domain of the bacterial protein LexA, since we had previously shown that this modified two-hybrid system exhibited an enhanced sensitivity for the interaction of GTPases with their cognate GEFs (Beranger et al., 1997) . Libraries were screened with the active region of murine Epac2
Figure 1 Strategy developed to generate novel dominant-negative mutants of the Rap1 GTPase encompassing the REM and CDC25 domains as a bait; this region also contains a Ras binding domain that is actually able to bind Ras, but not Rap (Bos, 2003 , and data not shown). The procedure was performed at 371C with the aim to select mutants that would be stable and active at this temperature and could hence be used in mammalian cells. It is interesting to note that, whereas the robust interaction between Ras[S17N] and the Ras GEF SOS was not affected by increasing the temperature from 30 to 371C, the relatively weaker interaction observed between Rap1[S17N] and Epac2 was notably reduced at the higher temperature (data not shown). Since we wished to select for mutants exhibiting a stronger interaction with Epac2 than that of Rap1[S17N], we increased the screening stringency by adding 10 mM 3-aminotriazole (3-AT; a competitive inhibitor of imidazole-glycerolphosphate dehydratase, the enzyme encoded by the yeast HIS3 reporter gene) to the selective medium, a condition that totally abrogated the Rap1[S17N]-Epac2 interaction (data not shown).
After cotransformation with the bait plasmid encoding the active region of Epac2, only yeasts transformed with libraries encoding mutants of codons 15, 16 and 17 were able to grow under selective conditions (data not shown). Plasmids were recovered from 10% of the selected colonies, and the nature of the mutations was determined by sequencing ( Figure 2a) ; 16 distinct mutants were identified under exhaustive screening conditions (see Materials and methods).
We then performed a 'counter-screen' to select only those mutants that no longer interacted with a panel of Rap1 effectors in the yeast two-hybrid system (RalGDS, AF-6, RGS14, PDZ-GEFI, B-Raf and Raf1); five of the initial mutants interacted with at least one such effector (in all cases, RalGDS) and were eliminated. We used a quantitative b-galactosidase assay to assess the relative interaction capacity of the mutants with Epac2 and RalGDS ( Figure 2b) ; whereas wild-type Rap1 poorly interacts with Epac2 and exhibits a very strong interaction with the effector RalGDS, those mutants that were retained after the counter-screen displayed symmetrically opposite properties. Analysis of the nature of the 11 potential dominant-negative mutants revealed that mutants at position 15 displayed the replacement of glycine by an acidic residue (aspartic or glutamic acid). Lys16 was found mutated to residues carrying a benzyl function (tyrosine and phenylalanine). Position 17 yielded the highest number of selected colonies exhibiting a larger variety of substitutions: although the majority of mutations encoded aliphatic (alanine, valine, isoleucine, leucine) or uncharged (proline, cysteine) residues, mutants carrying a glutamic acid at this position were also selected.
Interaction of Rap1 mutants with a panel of Rap1-GEFs
We then compared the ability of the 11 potential dominant-negative mutants to interact with other Rap1-GEFs such as C3G, CalDAG-GEFI, and members of the Epac family (Epac1 and GFR) in the yeast two-hybrid system using a quantitative b-galactosidase assay. As shown in Figure 3 , mutants of positions 15 and 16 displayed similar characteristics, clearly distinct from position 17 mutants: they interacted with all of the above-mentioned GEFs, showing a slight relative preference for C3G and CalDAG-GEFI over Epac family members. Conversely, mutants of position 17 (except for [S17P]) exhibited a selective pattern of interaction with GEFs. Whereas they all interacted with Epac family members, the [S17E] and [S17A] mutants were unable to interact with CalDAG-GEFI, and those carrying hydrophobic residues at position 17 (cysteine, valine, leucine, isoleucine) interacted neither with CalDAG-GEFI nor with C3G.
Interference with Rap1 activation induced by the overexpression of GEFs in mammalian cells
In order to assess whether these mutants exhibited dominant-negative properties, we initially measured their ability to inhibit the activation of endogenous Rap1 induced by the ectopic expression of Rap1-GEFs in mammalian cells. To this end, a constitutively active form of Epac2 (truncated from its cAMP binding regulatory domains) or full-length C3G and CalDAG-GEFI were expressed in HeLa cells, and the level of active Rap1 was measured by a pull-down assay using the Ras/Rap binding domain of RalGDS fused to GST (GST-RalGDS-RBD) (Franke et al., 1997) . In all cases, the minimal amount of expression vector yielding the maximal activation level of Rap1 (5-10-fold over the basal level in the absence of GEF; see Figure 4 ) was used; under these experimental conditions, the expression level of the GEFs was so low that we were unable to detect them by Western blotting (not shown).
Among the 11 mutants that displayed both an enhanced interaction with GEFs and reduced binding to effectors in the yeast two-hybrid assay, we focused on three representative ones: [G15D] interacting with all GEFs, [S17A] interacting with Epacs and C3G, and [S17I] selective for Epacs. Since our initial tests showed that the fusion of an HA-tag to the N-terminus of Rap1 inhibited by 50% the ability of Rap1A[S17A] to block the Epac2-induced activation of Rap1 (data not shown), all of the following experiments were performed with untagged Rap1 mutants. Their expression could still be visualized since the mutant proteins were usually overexpressed relative to endogenous Rap1. However, they migrated in the form of multiple bands, some with similar and others with slightly slower electrophoretic Figure 3 Interaction of Rap1 mutants with a panel of Rap1-GEFs. L40DGal4 yeast harbouring Rap1 mutants was crossed with Y187 yeast expressing GEFs of the Epac family (Epac1, Epac2 and Repac), C3G and CalDAG-GEFI; b-galactosidase activity was measured in lysates and normalized for the growth of yeast as in Figure 2b . Data are representative of three independent experiments performed with different yeast clones mobility than endogenous Rap1 in SDS-PAGE; such shifts are suggestive of defective post-translational processing, a phenomenon that is common for overexpressed Ras family proteins (Hancock et al., 1991) . The fact that the mutants gave rise to such multiple bands prevented us from distinguishing endogenous from ectopically expressed Rap1 proteins; since we were unable to measure the respective amounts of endogenous Rap1 and ectopically expressed Rap1 mutants, the levels of Rap1-GTP in all experiments were normalized relative to the expression of actin. Consistently with the results obtained in the yeast two-hybrid system, the mutants did not bind to GST-RalGDS-RBD, and hence did not interfere with the Rap1 activation assay.
As shown in Figure 4 , all of the tested mutants were able, albeit to different extents, to inhibit the activation of Rap1 induced by the ectopic expression of GEFs. Rap1A[S17A] behaved as the most potent and widespectrum mutant since it inhibited by more than 70% the activation of endogenous Rap1 induced by all three GEFs. However, the potential selectivity of the mutants suggested by the yeast two-hybrid assays was not confirmed in HeLa cells. For instance, Rap1A[S17I], which exhibited no interaction with C3G in the yeast two-hybrid assay, was able to inhibit partially the activation of Rap1 induced by C3G, and Rap1A[S17A], which did not interact with CalDAG-GEFI in the yeast two-hybrid assay, was the most efficient at inhibiting its action in HeLa cells. Moreover, Rap1[S17N] was able to inhibit partially the activation of Rap1 induced by the expression of all three GEFs, although it interacted very weakly with them in the yeast two-hybrid assay (Figure 3 ). These results suggest that the mechanisms underlying the dominant-negative properties of Rap1 mutants may be more complex than the simple titration of GEFs.
Interference with the activation of Rap1 induced by the physiological stimulation of endogenous GEFs
In order to address the dominant-negative properties of mutants under physiologically relevant conditions, we made use of biological models where a given stimulus was demonstrated to activate Rap1 via a single identified GEF using its endogenous pathway. In CHO cells expressing the serotonin 5HT4b receptor, serotonin and forskolin, which stimulate the elevation of intracellular cAMP levels, were shown to activate Rap1 through Epac1 (Maillet et al., 2003) . Under these conditions, the activation of Rap1 elicited by the treatment of cells with forskolin was partially inhibited by the expression of Rap1A[S17A] ( Figure 5 ); in contrast, Rap1[S17N], Rap1[G15D] and Rap1[S17I] had no effect. This result is consistent with the fact that the Rap1A[S17A] mutant exhibited the best interaction with Epac1 in the yeast two-hybrid assay (Figure 3) .
In Cos1 and PC-12 cells, EGF activates Rap1 via the recruitment of a Crk-C3G complex to the EGF receptor, a mechanism that requires the tyrosine phosphorylation of C3G (Ichiba et al., 1999) . Using Cos7 cells, we verified that EGF rapidly led to the At 24 h after transfection, cells were deprived of serum overnight, lysed with detergents and lysates were cleared by centrifugation. The amount of Rap1 in the soluble cell lysate, originating from endogenous wild-type Rap1 as well as ectopically expressed mutants, was assessed by Western blotting (soluble Rap1), and the levels of Rap1-GTP were measured by a RalGDS pull-down assay as described in Materials and methods. Results were normalized relative to the amount of actin measured on the same blot; their quantification as per cent of the level of Rap1-GTP resulting from the expression of GEFs alone is shown below each blot. The data are representative of three independent experiments. (b) Quantitative analysis of Rap1-GTP levels. Results represent the mean7standard deviation of three independent experimental determinations with each GEF as in panel a activation of Rap1, and that this pathway involved C3G since expression of a C3G mutant carrying a deletion of its catalytic domain (M Matsuda, personal communication) exhibited an inhibitory effect ( Figure 6 ). In these cells, Rap1[S17N] and Rap1[S17I] failed to inhibit the EGF-induced activation of Rap1, whereas Rap1A[-S17A] and Rap1[G15D] partially blocked it (Figure 6 ), results that are consistent with the selective ability of these mutants to interact with C3G in the yeast two-hybrid assay (Figure 3) . We observed that a significant proportion of the dominant-negative mutant proteins ectopically expressed in COS, and to a lesser extent in CHO cells, could not be solubilized by nonionic detergents under conditions where endogenous Rap1, as well as ectopically expressed wild-type Rap1 (not shown), were readily extracted; indeed, insolubility of GTPase dominant-negative mutants, presumably nucleotide-free and partially denatured, has been observed by many investigators (Ferguson and Higashijima, 1991 Figure 5 Interference of potential dominant-negative mutants with the activation of Rap1 induced by the endogenous cAMPEpac1 pathway in CHO cells. CHO-5HT4b cells stably expressing the serotonin 5HT4b receptor were grown in 85 mm diameter dishes and transfected with 10 mg of pRK5 vector, either empty or expressing Rap1 mutants. At 24 h after transfection, cells were deprived of serum overnight and treated for 10 min with 10 mM forskolin. They were lysed with detergents and a portion of the crude lysate was removed to determine the total level of expressed Rap1; the lysate was then centrifuged and processed as in Figure 4 to measure the levels of Rap1-GTP and soluble Rap1. (Hariharan et al., 1991; Asha et al., 1999) . Moreover, experiments with mutant somatic cell clones have shown that D-Rap1 is required for viability in a cell-autonomous manner (Asha et al., 1999) . We generated transgenic flies containing the DRap1[S17A] transgene under the control of a UAS sequence and used the Gal4-UAS transcription system to activate the expression of this transgene (Brand and Perrimon, 1993) . These flies were crossed with a GMRGal4 strain in order to drive expression of the transgene in all differentiating cells of the eye imaginal disc (Hay et al., 1997) . This experiment was performed with 10 independently established transgenic UAS-D-Rap1[-S17A] lines; a strong 'eye-reduced' phenotype together with varying degrees of lethality was observed for seven lines, and total lethality at the late pupal stage was observed for three lines (data not shown). To establish that the observed lethality was due to the GMR-driven overexpression of the dominant-negative D-Rap1[S17A] protein, we coexpressed it with transgenes encoding proteins that should overcome the titration of GEFs by the D-Rap1[S17A] mutant, and therefore rescue viability. These experiments were performed with transgenic lines carrying insertions of the D-Rap1[S17A] transgene such that its expression under the control of GMR-Gal4 caused 100% pupal lethality. Overexpression of wildtype D-Rap1 restored viability in 100% of the DRap1[S17A] transgenic flies (Table 1) ; however, these flies displayed a reduced eye phenotype. Interestingly, rescue by a transgene encoding an activated form of Rap1 (D-Rap1[G12V]) also resulted in total lethality rescue, yet these flies exhibited almost normal eyes (Table 1) . This effect was specific to Rap1, since neither the expression of Ras1 nor that of a constitutively active D-RalA[G20V] was able to rescue the lethality of the flies.
We then assessed the ability of overexpressed Drosophila D-Rap1 GEFs to rescue the lethal effect of DRap1[S17A] expression. As shown in Table 1 , neither D-C3G nor D-PDZGEF, alone or in combination, was able to suppress lethality of the GMR-driven expression of the D-Rap1[S17A] transgene. In order to investigate whether the overexpression of D-Epac could rescue the lethality of D-Rap1[S17A], we used a truncated fragment of D-Epac devoid of cAMP regulatory sequences, which was targeted to membranes by the fusion to its C-terminus of the 18 C-terminal residues of human K-Ras (Epac Act ). Furthermore, since D-Epac efficiently binds activated Ras1 through its RA domain and could titrate it when overexpressed resulting in artefactual phenotypes (S L'Hoste, unpublished observations), this domain was inactivated by introducing a K549A point mutation (Bos, 2003; S L'Hoste, unpublished 
data). Expression of the D-Epac
Act
[K549A] transgene under the control of GMR-Gal4 was viable and resulted in eyes with a normal size, but exhibiting a rough eye phenotype; we selected two such transgenic lines, K6L that exhibited a weaker, and K6Y a stronger, eye phenotype. The cross of K6L with D-Rap1[S17A] transgenic flies resulted in a partial viability rescue, producing flies that exhibited an eyeless phenotype (see Table 1 ); in contrast, crossing with K6Y flies resulted in a total viability rescue producing flies with normal-sized eyes. This result suggests that D-Epac is able to titrate D-Rap1[S17A] in a dose-dependent manner. Taken together, these results indicate that the D-Rap1[S17A] mutant behaves genetically as a dominant-negative Rap1 in vivo.
Discussion
The absence of suitable Rap1 dominant-negative mutants has been a limitation to study the involvement of this GTPase in signalling pathways. We have therefore devised and carried out a strategy to generate novel dominant-negative mutants of the Ras-related GTPase Rap1, which consists in three successive steps: (i) we targeted for mutagenesis a specific region of the protein involved in binding the b and g phosphates of GTP as well as interacting with GEFs (Biou and Cherfils, 2004) , the P-loop. Instead of aiming to randomly mutagenize the full-length protein, targeting this defined region of Rap1 enabled to minimize the risk of selecting mutants that could be affected in other functions than binding GEFs, such as their post-translational processing or association with potential scaffolding proteins, which could be important for their biological activity. Furthermore, the insertion of oligonucleotides carrying each a totally degenerated codon enabled us to generate for each of the targeted positions (residues 14-19) single amino-acid changes covering the whole spectrum of residues (with theoretical frequencies defined by the genetic code) without heavily favouring the mutations resulting from only one base change, as compared to those requiring two or three base changes in the same codon. Indeed, several of the mutations selected in this procedure, such as Rap1[G15D] that we have shown to exhibit dominant-negative properties, were generated by the change of two (and even three in one case) base pairs.
(ii) The selection step consisted in a yeast twohybrid screen designed to obtain mutants exhibiting an increased interaction with the Rap GEF Epac2. We used 3-AT, a competitive inhibitor of the product of the HIS3 reporter gene enabling the growth of yeast bearing positive two-hybrid interactions on medium lacking histidine, to adjust the 'stringency' of the screen so that only those mutants displaying stronger interactions than Rap1[S17N] with Epac2 would be selected. (iii) Finally, we carried out a 'counter-screen' to eliminate the mutants still interacting with Rap1 effectors and therefore susceptible to affect (by activation or titration) downstream pathways. Consequently, the mutants selected by this procedure no longer bound RalGDS, and hence did not interfere with the pull-down assay used for the determination of Rap1-GTP levels in cell lysates. Although our mutant libraries covered equally residues 14-19, only mutants of positions 15, 16 and 17 exhibited an enhanced interaction with Epac2. The structures of Rap1-GTP bound to Raf (Nassar et al., 1995) and of the related Rap2 protein (Cherfils et al., 1997) show that these three residues are the closest to, and interact extensively with, the b and g phosphates of GDP and GTP: the NH of the main chain of all three residues interacts with the b phosphate, the NH3 of lysine 16 forms a hydrogen bonds with both b and g phosphates, and the OH of the side chain of serine 17 interacts through the Mg 2 þ ion with the b and g phosphates of GTP. Hence, mutations of these residues are predicted to impair critical interactions of guanine nucleotides with the P-loop, and therefore a reduction of the protein's affinity for nucleotides; this has indeed been shown for mutations of position 15 ([G15A]; Powers et al., 1989; Chen et al., 1994) Feig and Cooper, 1988; Farnsworth and Feig, 1991) . In Ras, these residues are also critical for the conformation of the nucleotide-free Ras-SOS complex (Boriack-Sjodin et al., 1998) (Figure 7a ): Gly15 undergoes a large displacement into the GDP binding pocket, Lys16 is engaged in an intramolecular hydrogen bond with Glu62 of Ras, which is made possible by a unique conformation of the switch 2 mediated by the GEF, and Ser17, which is the sole residue from the P-loop to form a direct contact with SOS, has moved from the position where it stabilizes the GDP-associated Mg 2 þ ion to form a hydrogen bond with Glu942 of SOS. Given that the Ploop is almost identical in Rap1 and Ras (Figure 7b) , and that the catalytic regions of Rap-GEFs and RasGEFs bear significant homology in their CDC25 domains, notably at helix H, which faces the P-loop in the nucleotide-free Ras-SOS complex (Figure 7c) , the Rap1-GEF complexes are likely to resemble the nucleotide-free Ras-SOS complex. Notably, the glutamate of SOS that interacts with Ser17 in Ras is conserved in Rap-GEFs of the Epac family but is replaced by a leucine in C3G and CalDAG-GEFI, a change that should impair the ability of Rap1 to form , 1988) , shown in transparency, labels in italics). Helix H of SOS is in cyan (residues 931-943, side chains in contact with Ras are shown in ball-and-stick, and marked with an asterisk in panel c), residues 14-19 from the P-loop of Ras are in red and the switch 2 of Ras is in yellow. Hydrogen bonds are shown in dotted lines. Helix H contributes to stabilizing the nucleotide-free conformation of Ras by a hydrogen bond between Glu942 SOS and Ser17 Ras and by promoting a unique conformation of the switch 2 of Ras that allows an internal hydrogen bond between Lys16 (P-loop) and Glu62 (switch 2). Note that the nucleotide-free complex is incompatible with the binding of GDP (clashes with Gly15
Ras , Ser17
Ras and E942 SOS , Leu938 SOS , Lys939 SOS and Glu942 SOS that directly interact with Ras in the Ras-SOS complex are marked with asterisks such a hydrogen bond with these GEFs and may explain the differential ability of Ser17 mutations to interact with C3G and CalDAG-GEFI in our study (see Figure 3) . However, sequence variations at the other residues of Rap-GEFs that are predicted to face the Ploop (corresponding to Thr935, Leu938, Lys939 in SOS; see Figure 7a and b) may also contribute to the differential interactions of the mutants at positions 15, 16 and 17 with Rap-GEFs. The remarkable selectivity of the different mutants in the yeast two-hybrid assay, even if not sufficient to yield a dominant-negative effect in mammalian cells, argues in favour of such specific interactions at the nucleotide-free Rap1-GEF complex or Rap1-GDP-GEF intermediate.
Based on their differential abilities to interact with GEFs in the yeast two-hybrid assay, we chose three mutants to evaluate their potential dominant-negative properties in cellular models where Epac or C3G is activated via physiological stimuli. The lack of an appropriate biological model for the CalDAG-GEFI pathway prevented us from assessing the actual dominant-negative activity of our mutants towards this GEF. The results summarized in Table 2 show that Rap1[-S17A] acts as a dominant-negative mutant towards both C3G and Epac1, whereas Rap1A[G15D] acts only on C3G, and Rap1A[S17I] displays no effect. The effectiveness of the Rap1[S17A] mutant to act as a bona fide dominant-negative mutant was demonstrated in vivo during Drosophila development: (i) its expression phenocopies the pupal death observed in Rap1-defective mutants; (ii) this effect can be partially overcome by expression of wild-type D-Rap1, and totally by overexpressing the constitutively active D-Rap1[G12V] allele, but not by using another GTPase such as Ras1 and D-RalA; and (iii) the lethal effect of D-Rap1[S17A] is overcome in a dose-dependent manner by the overexpression of D-Epac.
The selective dominant-negative effects of Rap1 mutants in cell lines where endogenous C3G and Epac are activated by physiological stimuli were relatively consistent with the interaction efficiencies observed in the yeast two-hybrid system (see Figures 3, 5 and 6 and  Table 2 ). However, this selectivity was no longer found when the activity of mutants was assessed in cells ectopically expressing GEFs. Several factors may be critical for the activation of Rap1 by its endogenous GEFs in response to physiological stimuli, such as (i) their subcellular localization, (ii) assembly into multimolecular structures (via scaffolding proteins for instance) and (iii) pathway of activation involving posttranslational modifications, as is the case for C3G (Ichiba et al., 1999) , and/or conformational changes, as shown for Epac (Bos, 2003) , both of which may also influence the subcellular localization of GEFs and their interaction with other proteins. These mechanisms may no longer be operative with ectopically expressed GEFs, especially since they only activate Rap1 on the basis of their overexpression in the absence of physiological stimuli (we used the wild-type protein for C3G and a constitutively active mutant for Epac). This may form the basis for the lack of specificity of the mutant Rap1 proteins towards ectopically expressed GEFs, and explain our observation that it is only in this 'artificial' assay that Rap1A[S17I] displays dominant-negative activity towards C3G and Epac, and that Rap1[G15D] acts almost as effectively as Rap1[S17A] to inhibit the activity of Epac. This is also the only experimental setting in which Rap1[S17N] displayed a dominantnegative effect in our hands, since this mutant was ineffective versus C3G and Epac activated in cells by EGF and cAMP, respectively, despite the fact that its level of expression and solubility were as good or better than those of the other mutants. Studies from other laboratories have reported the dominantnegative effect of Rap1[S17N] on several Rap-dependent activities such as activation of the B-Raf-ERK pathway (Vossler et al., 1997) and integrin-dependent adhesion (Reedquist et al., 2000) , as well as on the activation of Rap1 by isoproterenol in HEK293 cells (Shi et al., 2004) ; this suggests that either these pathways operate through other GEFs to which this mutant binds with higher efficiency, or that Rap1[S17N] may act via other mechanisms than sequestering GEFs in a high-affinity nucleotide-free bimolecular complex.
A recent study aimed at isolating dominant-negative Rap1 mutants, generated by random mutagenesis, that display an increased interaction with C3G led to the characterization of a triple mutant, 'Rap1AGE', that carries an [S17A] substitution in the P-loop, as well as two additional replacements, [V29G] and [K117E], affecting residues that interact with the ribose moiety of GTP (Shi et al., 2004) . The authors indeed show that this mutant inhibits the activation of Rap1 by C3G (endogenous as well as an ectopically expressed constitutively active form) in HEK293 cells, consistent with our findings with the single Rap1[S17A] mutant. However, they found that Rap1AGE was unable to inhibit the activation of Rap1 by Epac; since these authors used an experimental setting where the GEF was vastly overexpressed relative to the endogenous protein, this precludes any valid comparison concerning Epac with the results presented in this study.
In conclusion, we have generated and selected novel dominant-negative mutants of the Rap1 GTPase. One such mutant, Rap1[S17A], acts in mammalian cells as a dominant negative on the physiological activation of the cAMP-Epac and EGF-C3G pathways, whereas another mutant, Rap1[G15D], is selectively active on the 
EGF-C3G pathway. It is likely that by applying a similar selection procedure to other Rap-GEFs, it would be possible to isolate and characterize mutants specific for each of the Rap1 GEFs, or at least for various GEF subgroups. The use of such mutants could be instrumental in determining which upstream pathway(s) is(are) responsible for the activation of Rap1 in physiological processes that involve the action of this GTPase. By extension, the method for generating and selecting mutants that we describe in this study could be transposed to generate selective dominant-negative mutants for other GTPases and signalling molecules.
Materials and methods
Constructs
Rap1 GEFs and effectors were expressed in yeast fused Cterminally to the activation domain of Gal4 from pACT2 (Clontech) and pGAD-GH vectors, respectively. Sequences encoding the region encompassing both the REM and CDC25 domains of murine Epac2 (451-993), human Epac1 (311-881), human Repac (4-444), human C3G (641-1077) or human CalDAG-GEF1 (3-430) were, respectively, amplified by PCR from pcDNA3.0-mEpac2 (G Gaudriault, unpublished data), EST Image 2545556 (Research Genetics), KIAA0277 (Kazusa DNA Research Institute), pHSG-C3G (a gift from M Matsuda), pEXV-mycCalDAG-GEFI (a gift from J Hancock). Rap1 effectors were either full length (RGS14 (Traver et al., 2000) , Raf1 (Van Aelst et al., 1993) and B-Raf (Papin et al., 1996) ) or restricted to their regulatory region (RA domain of RalGDS (764-914); Nancy et al., 1999) , RA domain of AF-6 (1-140) (Boettner et al., 2000) or RA and PDZ domains of PDZ-GEFI (270-765) (a gift from J Flanders). For their expression in mammalian cells, the coding sequences of Rap1A mutants were amplified by PCR from the selected yeast plasmids and cloned into pRK5. The catalytic region of Epac2 (REM and CDC25 domains, residues 463-1011) was expressed fused C-terminally to the myristoylation domain of c-Src in the pcDNA3.0 vector. pExv-mycCalDAG-GEFI (Clyde-Smith et al., 2000) was kindly provided by J Hancok. pHSG-C3G (Ichiba et al., 1999) expressing fulllength C3G (residues 1-1078) and pCAGGS-C3GDCD expressing a mutant C3G protein (residues 1-826) deleted from its C-terminal catalytic domain were generous gifts from M Matsuda.
Construction of Rap1 mutant libraries and yeast two-hybrid screening
Full-length human Rap1A was expressed as a C-terminal fusion to the DNA binding domain of LexA in pFBL23 (Beranger et al., 1997) . Its coding sequence was amplified by PCR using oligonucleotides 5 0 -CCTGAATTCGCCATGCGT GAGTACAAGCTAGTGGTCCTTGGATCCTCAGAGTG TACAGTTTGTTCAGGGAATTTTTG-3 0 and 5 0 -CCTGTC GACGAGCAG CAGACATGATTTCTT-3 0 , which enabled to introduce silent BamHI and BsrGI restriction sites surrounding the sequence encompassing residues 12-20 of Rap1A. Six individual libraries of Rap1A mutants, each for one of the 14-19 codons, were constructed by replacing the BamHI-BsrGI fragment by short double-stranded DNA fragments generated by hybridization of two oligonucleotides totally degenerated for the concerned codon (Figure 1 ). DH5a Escherichia coli were transformed with the ligation products, plated on LB medium containing 50 mg/ml ampicillin, and DNA was prepared by standard methods. Each library had a complexity of more than 10 5 independent clones in E. coli, ensuring that the 64 codons of the genetic code should be largely represented in the Rap1 mutant libraries. For screening, DNA from each library was cotransformed with pACT2-Epac2 in L40DGal4 yeast (a gift from P Legrain and M Fromont-Racine) and plated on selective medium lacking tryptophane, leucine and histidine, and supplemented with 10 mM 3-AT. We checked that under these conditions, more than 10 4 independent yeast colonies were generated (on medium lacking tryptophane and leucine), ensuring that the screen was exhaustive. pFBL23 plasmids were recovered from individual colonies, and selected Rap1A mutations were identified by sequencing. For counter-screening relative to their lack of interaction with effectors, L40DGal4 yeast harbouring selected Rap1A mutants were mated with Y187 yeast (Clontech) transformed with effectors expressed from pGAD-GH vectors. Yeasts were handled according to standard techniques, and two-hybrid assays were performed as previously described (Nancy et al., 1999) . Quantitative bgalactosidase assays were performed on duplicate samples according to Transy and Legrain (1995) ; results were normalized for the relative growth of yeast clones estimated by their absorbance at 600 nm.
Cell culture, transfection and stimulation
HeLa and Cos7 cells were grown in DMEM containing 10% fetal bovine serum. They were transfected with Exgene 300 (Euromedex) and Lipofectamine Plus reagents (Invitrogen), respectively. CHO cells expressing the serotonin 5HT4b receptor and b-APP were a kind gift from F Lezoualc'h (Maillet et al., 2003) . They were grown in HamF12 medium containing 10% fetal bovine serum, 20 mM Hepes, 50 nM geneticin and 50 nM hygromycin, and transfected with Lipofectamine 2000 (Invitrogen). At 24 h after transfection, cells were deprived of serum overnight. Cos7 and CHO cells were stimulated for 5 min with 10 mM EGF (Oncogene) or 10 mM forskolin (Calbiochem), respectively, prior to harvesting.
Rap1 activation assays and immunoblotting
The levels of Rap1-GTP were measured as described previously (Franke et al., 1997) . Briefly, cells were washed with cold PBS and lysed with a buffer containing 50 mM TrisHCl pH 7.5, 15 mM NaCl, 20 mM MgCl 2 , 5 mM EGTA, 1% Triton X-100, 1% N-octylglucoside, 100 mM PMSF, 10 mM leupeptin and 10 mM aprotinin. Lysates were cleared by centrifugation, and Rap-GTP complexes were recovered on glutathione-Sepharose beads precoupled to GST fused with the Ras/Rap binding domain of RalGDS. Precipitates were washed three times with lysis buffer and solubilized in SDS sample buffer. Portions of both the total (before centrifugation) and soluble (after centrifugation) cell lysates were kept for detection of total and soluble Rap1 contents, respectively. Following Western blotting, Rap1 was detected with affinity-purified polyclonal antibodies (Beranger et al., 1991) . Actin was detected with monoclonal AC-74 antib-actin (Sigma) antibody, and C3G with rabbit anti-G3G antibodies (Ichiba et al., 1999) . Proteins were visualized on Western blots by chemiluminescence (SuperSignal West Femto, Pierce); images were captured with a FUJI LAS-1000 CCD camera and quantified using FUJI Image Gauge software.
